BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 8387464)

  • 1. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Groot K; Halmos G
    Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and high dose of somatostatin analogue RC-160 on nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Cai RZ; Radulovic S; Milovanovic S; Szoke B
    Cancer Res; 1991 Nov; 51(21):5980-6. PubMed ID: 1682039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment of nitrosamine-induced pancreatic cancers in hamsters with analogs of LH-RH and a bombesin/GRP antagonist.
    Szepshazi K; Halmos G; Groot K; Schally AV
    Int J Pancreatol; 1994; 16(2-3):141-9. PubMed ID: 7868940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.
    Szepesházi K; Halmos G; Schally AV; Arencibia JM; Groot K; Vadillo-Buenfil M; Rodriguez-Martin E
    J Cancer Res Clin Oncol; 1999; 125(8-9):444-52. PubMed ID: 10480336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
    Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S
    J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
    Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.
    Halmos G; Schally AV
    Proc Natl Acad Sci U S A; 1997 Feb; 94(3):956-60. PubMed ID: 9023364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine effects of new bombesin/gastrin-releasing peptide antagonists in rats.
    Pinski J; Yano T; Groot K; Cai RZ; Radulovic S; Schally AV
    Am J Physiol; 1992 Oct; 263(4 Pt 1):E712-7. PubMed ID: 1415689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.
    Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV
    Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice.
    Radulovic S; Schally AV; Reile H; Halmos G; Szepeshazi K; Groot K; Milovanovic S; Miller G; Yano T
    Acta Oncol; 1994; 33(6):693-701. PubMed ID: 7946450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
    Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
    Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological effects and receptor binding affinities of new pseudononapeptide bombesin/GRP receptor antagonists with N-terminal D-Trp or D-Tpi.
    Radulovic S; Cai RZ; Serfozo P; Groot K; Redding TW; Pinski J; Schally AV
    Int J Pept Protein Res; 1991 Dec; 38(6):593-600. PubMed ID: 1726427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160.
    Pinski J; Halmos G; Yano T; Szepeshazi K; Qin Y; Ertl T; Schally AV
    Int J Cancer; 1994 May; 57(4):574-80. PubMed ID: 7910153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice.
    Shirahige Y; Cai RZ; Szepeshazi K; Halmos G; Pinski J; Groot K; Schally AV
    Biomed Pharmacother; 1994; 48(10):465-72. PubMed ID: 7858155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High potency of a new bombesin antagonist (RC-3095) in inhibiting serum gastrin levels; comparison of different routes of administration.
    Pinski J; Yano T; Rekasi Z; Cai RZ; Radulovic S; Schally AV
    Regul Pept; 1992 Oct; 41(3):185-93. PubMed ID: 1438988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice.
    Pinski J; Schally AV; Halmos G; Szepeshazi K
    Int J Cancer; 1993 Dec; 55(6):963-7. PubMed ID: 7902829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.